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When Will The Biology of Aging Become Useful? Future 
Landmarks in Biomedical Gerontology 
Richard A. Miller, MD, PhD 
Where should we look to find the causes of and cure for 
aging? This essay considers a number of scientific discoveries, 
not yet made, that might dramatically increase the propor- 
tion of biogerontologists doing useful work. I will consider, 
in turn, problems and prospects in the areas of comparative 
biology, mammalian and invertebrate genetics, biomarker 
research, caloric restriction, and clonal senescence and then 
conclude with a discussion of potential links between aging 
and late life disease. J Am Geriatr SOC 45:1258-1267, 1997. 
iogerontologists - members of the small cadre of re- B searchers obsessed with the basic biology of aging and its 
putative links to disease -cannot yet look you straight in the 
eye and state honestly that they are doing useful research, 
research that is bound to reveal the secrets of aging and 
thereby lead to improvements in human well-being. Aging, 
despite centuries of descriptive work and decades of progres- 
sively more thoughtful hypothesis-driven studies, and despite 
the fascination that the topic holds for lay and professional 
public alike, has not yet taken the step up from mystery to 
problem. Infection before the discovery of microbes, optics 
before the discovery of the photon, genetics before the double 
helix, astronomy before the law of gravitation: all were 
mysteries in the same sense that biogerontology is today, i.e., 
domains of study in which thoughtful, well-read, industrious 
investigators could not be certain that their particular tunnel 
had a light at the other end. At a time when many biomedical 
journals are devoting increasing attention to the aged and to 
aging, to gerontology and to geriatric medicine, it seems 
appropriate to compile a list of imaginary future landmarks, 
a set of scientific results that have not yet been discovered but 
whose discovery might break open the aging problem and 
convert it into a topic suitable for lucid discourse, a mappable 
terrain for exploration. 
Before discussing cases, it will be helpful to venture a 
definition of a tendentious term, not to settle controversies ex 
cathedra but to provide a common vocabulary throughout 
this essay. I will use the term aging to refer to the process that 
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gradually turns healthy adults - teen-age humans or 8 week 
old mice - into frail older individuals with a diminished 
capacity for surviving threats, including infectious agents, the 
stress of surgery or cold weather, or physical dangers such as 
onrushing buses or owls. This definition excludes, arbitrarily, 
perhaps, though 1 think in a helpful way, such phenomena as 
(1) the aging of cheese, wine, and beef, (2) the senescence 
process that leads to leaf abscission, (3) the aging of erythro- 
cytes that leads to their removal from circulation, (4) the 
processes that convert embryos into babies and babies into 
teen-agers, (5) apoptosis or programmed cell death, (6) what 
happens to salmon after upstream mating, and (7) the process 
that converts early passage diploid cells into late passage cells 
incapable of further cell division. All of the phenomena on 
this exclusion list are highly interesting and deserve intensive 
study, and it may that the exploration of one or more of these 
processes will lead to improved understanding of biological 
aging per se. Nothing is gained, however, from the confusion 
that can result from using the term aging indiscriminately to 
refer to some ill-defined subset of the phenomena listed 
above. The ideas that embryogenic development sets seeds 
that later bloom into senescent changes, or that clonal senes- 
cence underlies some or all late-life illnesses, or that post- 
reproductive decline in semelparous fish might provide in- 
sights into aging as it affects most mammals - ideas of this 
kind require careful specification and testing, an analytical 
process that is impeded by the reckless assumption that they 
are “merely different varieties of aging.” 
A second, related semantic obstacle comes from the 
intimate connection between aging and disease, often encap- 
sulated in the assertion (from a physician colleague) that 
“aging is just disease” or (from a veterinary pathologist) that 
“aging is just the sum of lesions.” These perspectives confuse 
process with result. While analysis of the pathogenesis of 
specific illnesses and specific lesions is undoubtedly a worthy 
occupation, the key challenge for biogerontology seems to me 
to discover the basis for intraspecies synchrony (and interspe- 
cies homology) among the many diseases and lesions, and the 
subclinical declines and predictable changes in tissue archi- 
tecture that accumulate in old age. Atherosclerotic compro- 
mise of key circulatory pathways, bothersome loss of muscle 
strength and joint flexibility, slowed reflexes and slowed 
immune responses, declines in one or more special senses, 
diminished short-term memory and processing speed, altered 
glucose tolerance and fat metabolism, preneoplastic changes 
or frank neoplasia: although no 80 year-old person (or 3 year 
old mouse) will exhibit all such changes, it is very rare to find 
an aged individual who exhibits none of these signs, and 
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equally rare to find a 16 year-old person bothered by any of 
them. The special challenge for biological aging research is to 
figure out why it is so easy to distinguish teen-agers from their 
grandparents, to discover the hidden links among these dis- 
parate disadvantages, and to discover why humans can avoid 
for decades the pathophysiological decline that afflicts 2- 
year-old mice and 10-year-old dogs. 
It is now unfashionable to refer to aging as a single 
process and much more acceptable to consider aging as a 
group of processes that work in parallel.’ The idea of multi- 
ple processes has much to recommend it because it is indeed 
difficult to suggest a single influence that might lead simulta- 
neously to such diverse outcomes as changes in cross-linking 
of extracellular proteins and altered gene expression in many 
cell types, to hyperproliferation of cells we could do without, 
to poor proliferation of cells we need, and to diminished 
responsiveness in cells that do not proliferate at all. And yet 
the coordinated retardation of this whole set of processes has 
indeed occurred repeatedly in the independent evolution of 
multiple clades of long-lived animals from shorter-lived an- 
cestors: the progenitors of bats,2 birds, flying squirrels, ele- 
phants, turtles, chimps and island-bound opossums3 have all 
managed this trick when they found themselves in ecological 
niches in which delayed reproduction could pay off in Dar- 
winian fitness. Evolution, constructing a new form, does not 
start with a blank page but rather morphs by pulling a 
minimum of well connected strings. Turning a wolf into a 
Chihuahua or a mastiff, or a hamster brain into a monkey 
brain,4 does not involve mutations in large sets of genes of 
similar purpose (the gene for shorter leg bones, the gene for 
shorter jaw, the gene for shorter esophagus. . . ) but instead 
must involve mutations in a small number of loci that act to 
control, directly or indirectly, a wide range of interconnected 
downstream processes. In the gerontological context, a new 
allele that postponed tumor development (or atherosclerosis 
or cataracts or osteoporosis) for 40 years in a short-lived 
primate would have little survival value on a genetic back- 
ground that permitted fatal declines in muscle or immune 
strength in the first decade of life. Genes that slow down the 
rate of degeneration of only a single physiological system are 
not likely to have much effect on reproduction or survival at  
advanced ages; only mutations at  loci that slow down the rate 
of change of a wide range of senescent processes are likely to 
have much survival value in species that find themselves in 
low risk niches that select for longevity. Thus, the idea that 
aging involves a concurrence of multiple processes, each 
under independent genetic control, that just happen to all 
occur much more slowly in people than in dogs, and more 
slowly still in mice, seems improbable. 
The caloric restriction (CR) phenomenon also highlights 
the implausibility of the multiple process view of aging. 
Nearly all of the effects of aging, including changes in gene 
expression, cell communication, extracellular matrices, and 
disease risks, can be retarded in parallel by caloric restriction 
of laboratory rodents.” Although the mechanism of CR is still 
unknown, it is hard to believe that a unimodal intervention of 
this kind would, by a bizarre coincidence, retard such a wide 
range of age-sensitive processes unless the rates of these 
processes were themselves at  least partly coupled. 
The tension between the concept of aging as a unitary 
process and the idea of aging as a set of distinct processes can 
perhaps be clarified by an analogy. In some ways an aging 
organism might be modeled as a complex system of water 
pipes, connected by a system of valves and side channels, with 
fluid entering from a reservoir at the top and leaving through 
various taps and drainspouts. Differences among individuals 
in the pattern of flow could be influenced by many factors, 
including the diameter of the individual pipes and connec- 
tors, the set point of the various valves, and the activities of 
sensors that regulate flow in distant channels based upon 
flow, or turbulence, or acceleration of liquid in monitored 
pipes. This plumbing system, like an aging organism, has 
many interdependent yet distinct processes in action simulta- 
neously, each of which may have some influence on the time 
at  which the supply cistern becomes exhausted. An evolution- 
ary process, or an intervention like caloric restriction, might 
extend the lifespan of the system by tightening each of the 
values and narrowing each of the tubes proportionately and 
simultaneously - a tricky approach - or might accomplish the 
same thing more simply by replacing the water with glycerol. 
The single process model of mammalian aging can be seen as 
a search for the factors regulating the viscosity of the fluid 
coursing through the multiple channels of life history, and the 
speciation and caloric restriction arguments can be taken as 
encouraging hints that the factors may be manageably few in 
number. 
Where, then, does it now seem worthwhile to look for 
the biochemical basis of the aging process? The remainder of 
this essay will consider several proposed answers, each with 
its advocates, none yet wholly successful. We will consider, in 
turn, problems and prospects in the areas of comparative 
biology, mammalian and invertebrate genetics, biomarker 
research, caloric restriction, and clonal senescence, and then 
conclude with a discussion of potential links between aging 
and late life disease. 
COMPARATIVE AND EVOLUTIONARY BIOLOGY 
In one sense the comparative biologists, with their cous- 
ins the quantitative geneticists, have already solved the prob- 
lem of aging by producing coherent, large\y confirmable 
explanations of how evolutionary forces regulate lifespan 
and other life history parameters. Details of this argument, 
traceable to ideas of Peter Medawar and George Williams,6 
quantified by Charlesworth and his students, and supported 
by and field3 data, are beyond the scope of this 
paper but can be sketched out in summary form. Consider a 
hypothetical species in which aging does not occur. Even in 
the absence of aging, the mortality rate cannot be zero; some 
factors, such as disease, predation, and bolts of lightening, 
will kill off some members of the population in any given 
period of time. In fact, with such a constant (and age- 
independent) risk of mortality, the survival of any given 
cohort will resemble the exponential decay curve of a given 
mass of a radioactive element. If for a particular species in a 
particular locale the risks are such that 50% of the popula- 
tion die each year, then 25% of a given cohort will be alive at 
the end of the second year, and 12.5% at the end of the third 
year. In such a situation, a mutation that increases the risk of 
a particular disease - such as cancer, or atherosclerosis, or 
immunosenescence leading to fatal influenza - in 1-year-old 
animals will be strongly selected against, because there are 
many 1 -year-old animals, each with an appreciable probabil- 
ity of contributing offspring to the next generation. A muta- 
tion that causes the same illnesses, but does so only in 
8-year-old animals, will, however, not be weeded out by the 
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forces of natural selection, because natural attrition has whit- 
tled the pool of 8-year-old animals to a negligible remnant, 
still by hypothesis healthy and fertile and no more likely to 
die this year than they were last year, but so few in number as 
to contribute very few genes to the next generation. Thus, 
genetic variations that cause disease only at older ages tend to 
accumulate. Mutations that improve survival or fertility at 
early ages (say the first 2 years in this example) will be 
strongly selected for, even if, as a pleiotropic side effect, they 
lead to illness and diminished fitness at later ages. These two 
factors, accumulation of harmful late-acting mutations and 
of mutations whose early beneficial effects are accompanied 
by later deleterious effects, generate an animal in which the 
chance of disease and physiological decrepitude become in- 
creasingly more likely at  older ages - in other words, an 
animal that ages. 
Now modify the environment. Remove the owls, install 
lightening rods, and kill off the mosquitoes that spread the 
infections. Under these new conditions survival to age 8, once 
very rare, becomes more likely, and alleles that cause degen- 
erative changes at this age are for the first time deleterious, 
and, thus, subject to evolutionary pressures. New alleles that 
postpone cancer, vascular disease, loss of reflexes, diabetes, 
and musculoskeletal frailty until the age of 20 are suddenly 
highly beneficial. The key prediction of this model, now 
confirmed by a variety of descriptive data and even some 
experimental evidence, is thus that environments where base- 
line risks are relatively low permit the evolution of species (or 
populations) in which senescent changes are also delayed. 
Species on predator-free islands, species that are big enough 
or have tough enough carapaces not to get eaten, mammals 
that learn to fly or glide-each of these conditions tends to 
evolve species or races with the potential for a long lifespan. 
The challenge now is to convert this satisfyingly com- 
plete, quantitative, explanatory framework into a set of new 
animal models for tackling the important questions of mech- 
anistic gerontology. There is a substantial tradition within 
aging research of trying to use comparative biology to ad- 
dress questions in cellular and molecular biology, but these 
efforts have too often suffered from a lack of the professional 
perspective that a sophisticated comparative biologist might 
have brought to the pr~ject.’”~ Plots of longevity against 
specific biochemical or cellular parameters, such as fibroblast 
expansion limits or cytochrome levels or DNA repair capa- 
bilities, have from time to time suggested a relationship 
between the trait of interest and species-specific longevity, 
but they suffer from an arbitrary and often ill-considered 
selection of species chosen for their familiarity rather than on 
the basis of evolutionary relationships. Plots of fibroblast 
expansion limits versus species longevity can, for example, be 
generated with positive, negative, or level slopes, depending 
on selection of species and adjustment for body size (see 
Figure 1) .  Comparison of outbred white-footed mice (genus 
Peromyscus) to inbred laboratory mice (genus Mus) may be 
tempting, based on superficial similarities, but such hasty 
comparisons overlook the rather distant evolutionary rela- 
tionship between these two species as well as the confounding 
influences of laboratory adaptation and inbreeding. Claims 
that the remarkably long lives of bats reflect merely the effects 
of hibernation can be overturned sim ly by looking up the 
of brain weight to body weight provides a useful predictor of 
lifespan among species seem less remarkable when one notes 
lifespans of bats that do  not hibernate 4 ; claims that the ratio 
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Figure 1. Two plots showing inter-species comparisons of fibro- 
blast culture data with species longevity. The top panel shows 
data from reference (58); fibroblasts were cultured until growth 
cessation, and the logarithm of the number of population dou- 
blings was plotted against the logarithm of the maximal longev- 
ity for the species. The correlation is highly significant. The 
bottom figure shows these data after adjustment for differences 
in the number of doublings needed to account for differences in 
body size relative to the smallest species (bat). Thus for example, 
the population doubling value for horses was reduced by 28.8 to 
14 to reflect the need for 14.8 cell doublings to create a horse- 
sized body from a bat-sized body. With this adjustment the 
strenght of the correlation (R = .91, P = .001) is determined 
almost entirely by the values for humans, which exhibit both 
extreme longevity and extreme growth potential. Exclusion of 
the single point for human data yields the curve shown in the 
figure, where R = .37, P = .46. The dashed line with question 
marks indicates that the lifespan for the bat species used in 
reference (58) is unknown; other bats in this subfamily (N = 38) 
have maximum documented lifespan ranging from 5 to 32 years. 
This result suggests that the claimed relationship between fibro- 
blast growth potential and species longevity largely reflects the 
dependence of both measurements on body size, together with 
the atypical properties of human cells. The bottom panel and 
associated calculations were provided by Dr. Steven Austad. 
that ratios of liver, heart, spleen, or kidney weight to body 
weight are even better predictors.” 
Thus the comparative tradition in biogerontology has a 
checkered past. It is not hard, however, to imagine ways in 
which the comparative perspective might be used to develop 
new models to test ideas about the aging process. Ideas about 
the importance of oxidative damage in the aging process 
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might benefit from studies of bird species that combine high 
rates of fuel utilization with long lifespan.12 Island popula- 
tions, which can be long-lived in comparison with closely 
related mainland pop~la t ions ,~  may also provide useful test 
systems for examining ideas about the way in which aging 
rate is controlled. Genetic crosses between long-lived island 
populations and their shorter-lived cousins may be very help- 
ful in defining the numbers, positions, and effects of longevi- 
ty-regulating loci. Field experiments in which fish are trans- 
ferred from high predation to low predation  condition^'^ can 
very quickly produce new populations that differ in matura- 
tion rate and body size; if further study showed that such 
populations also differed in aging rate, they (or mammalian 
analogues) could provide exceptionally valuable resources 
for the genetic and biochemical dissection of aging and its 
relation to late life diseases. Meeting this challenge will re- 
quire courage, imagination, and careful planning on the part 
of both bench scientists and those who fund them and pro- 
vide long-term support for development of new models. 
MUTANTS, INDUCED AND NATURAL 
The study of mutants, whether spontaneous or induced 
by transgenic and knockout technology, is certain to play an 
increasingly important role in reductionist gerontology and 
can be seen as a special case of comparative biology. The 
discovery of alleles that extend lifespan in invertebrates by 
three-fold or the creation of transgenic flies in 
which altered antioxidant defenses seem to extend lifespan,16 
and the cloning of the mutant gene for Werner’s syndrome, 
which seems to accelerate a subset of the physiological and 
pathological changes often seen in aged people,” all have 
earned widespread attention recently as important steps to- 
wards improved understanding of the biology of aging. It is 
tempting to overinterpret findings in this genre, and the 
caricature of Werner’s syndrome as a straightforward accel- 
eration of the aging process, though carefully avoided by 
most of the researchers involved in the analysis of WRN 
mutants, has proven irresistible for many popularizers de- 
spite the many differences, some of them very obvious, be- 
tween Werner’s patients and normal older individuals. Mu- 
tations that shorten the lifespan, such as the misnamed 
“senescence-accelerated mouse” lines,18 must always be 
viewed with great suspicion as models of aging because there 
are many ways to impair viability without interfering with 
aging per se, but mechanistic analysis of syndromes such as 
Werner’s, that appear to produce collections of traits that are 
rarely seen together except in the aged, seems likely to pro- 
vide new insights into aging not otherwise easily obtained. 
The mere existence of single gene mutations that lead to 
dramatic increases in longevity demands intellectual gyra- 
tions’’ for those who prefer to consider aging as a collection 
of independent processes that just happen to occur in rough 
synchrony in any one species since single alleles that, by 
chance, happen to retard all such processes to a similar extent 
seem unlikely to arise. 
Evaluation of claims for single gene retardation of aging 
requires careful assessment of the control strain( s) to which 
the mutant is compared. A recent publication has demon- 
strated” extended lifespan in mice bearing the mutation 
df/df, which leads to small size by inhibiting the development 
of growth hormone-producing pituitary cells, and other 
dwarf mice, such as the dw/dw homozygote, also seem re- 
markably long lived (K. Flurkey and D. Harrison, unpub- 
lished results). These reports, the first published evidence for 
single gene effects that extend lifespan in a mammal, could 
indicate important interactions between the aging process 
and the factors that control size in mammals, an interaction 
made more attractive by the negative correlations seen be- 
tween size and longevity in dogs2’ and, perhaps, other mam- 
mals. Caution is called for, however, until data become 
available to see if the effects of the dw and df alleles are also 
seen on a variety of genetic backgrounds; if these effects are 
seen only on the specific genetic backgrounds tested so far, 
their implications for theories of aging become more tenuous. 
Similarly, reports that transgenic flies exhibit extended lifes- 
pan16 are somewhat tempered by the realization that the 
extension is only in comparison with specific, short-lived 
control strains rather than in comparison with the lifespan of 
unmanipulated flies. These reservations may, one hopes, be 
merely temporary, and the increasing sophistication by which 
synthetic geneticists can now manufacture mice in which 
specific genes can be ablated, expressed at graded doses, or 
turned on or off at  specific times is certain to be a major 
influence in experimental gerontology for the foreseeable 
future. 
INVERTEBRATE GENETICS 
The scientists who study aging in nematode worms (Cue- 
norhabditis eleguns) and fruit flies (Drosophilu melano- 
guster) do so because of the tremendous power these two 
species provide for genetic analysis and genetic manipulation; 
but these researchers are well aware that neither species is a 
mammal. There is no particular reason to suspect that the 
processes that limit life in these two species have major roles 
to play in mammalian aging. There is, however, also no 
compelling reason to conclude that mammalian aging is so 
unlike invertebrate aging as to make the latter field certifiably 
useless. The processes that plague old people - atherosclero- 
sis, Alzheimer’s disease, immune senescence, various cancers 
- surely play no role in fly or worm mortality, whereas 
drowning in mashed bananas as a consequence of wing 
erosion is, conversely, a rare cause of death in mice and 
humans. But the cause of aging, as opposed to the cause of 
death, is, at this point, perfectly mysterious in all of these 
species. Thus an assessment of whether specific processes, 
such as oxidation damage or mitochondria1 dysfunction or 
gene dysregulation, play an important role in both human 
aging and aging of one or both invertebrate models can only 
be a matter of educated intuition, guesswork, or faith. Many 
fundamental discoveries about mammalian development 
have, to date, emerged from clues provided initially by studies 
of C. eleguns and/or D. melunoguster that it would be foolish 
to bet too heavily against the invertebrate models. 
The proof of this pudding, the future landmark study, 
may come from attempts to locate and analyze mammalian 
homologues of longevity-extending genes initially found in 
flies or worms. Recent work in worm genetics has produced 
at  least two remarkable breakthroughs although implications 
for mammalian aging are still uncertain. First, several 
have contributed to the demonstration that adult 
worms have a genetic pathway, normally silent in adult life, 
that when activated by mutation can extend lifespan by 
three-fold or more. The details of this pathway are now under 
intensive study; once the key players are cloned, it will be 
possible to formulate and test hypotheses about their mode of 
action and to seek for mammalian genes of similar sequence 
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and, possibly, related effects. Second, activation of this life- 
span-extending pathway by mutations in several different 
genes seems to increase the resistance of the worms to a 
variety of stresses including oxidation, UV damage, and 
thermal stress.12 It is certainly plausible, though not yet quite 
proven, that the lifespan effects of the mutations are them- 
selves mediated by the changes in stress resistance. If this idea 
proves correct, it will suggest experiments to alter aging rates, 
and consequently disease incidence, in mice or eventually, 
perhaps, in humans. 
BIOMARKER RESEARCH 
The key goal of biomarker research, a goal still very far 
from realization, is to develop a set of tests that can be 
performed, fairly early in life on either mice or humans, that 
can be used to identify individuals who are aging at  different 
rates. Some authorities argue23 that such a goal is nonsensi- 
cal, because the consequences of aging are uncoordinated, 
with each individual developing his or her own unique phe- 
notype in old age. In this view, assigning a single number as a 
“measure of biological age” is as hopeless an assignment as 
trying to quantitate beauty or virtue or talent along a single 
dimension. Others, myself among them, take a more optimis- 
tic perspective, but we must admit that no set of well vali- 
dated biomarker assays has yet been developed for mammals. 
The presence of confounding factors poses a major technical 
obstacle: even if, for example, measurement of T cell function 
or muscle endurance or nerve conduction time or collagen 
cross-linking could provide some indication of inter- 
individual differences in the hypothetical “rate of aging,” 
each of these and other similar candidate measures are also 
strongly influenced by a range of other influences, most of the 
them poorly understood. T cell subsets, some of them ro- 
bustly age-sensitive in both humans and mice, are also influ- 
enced by genetic polymorphisms, by chronic and acute 
stresses, by irradiation, by medication, and by infectious 
agents. To discern in all of this “noise” the tiny bit of effect 
hypothetically produced by individual variations in aging 
rates is difficult, and it might be impossible. 
Merely showing that a given assay changes with age, and 
thus distinguishes most old people from most young people, 
is not sufficient to qualify a test as a biomarker. What counts 
is showing that the test in question divides people (or mice) of 
a given age into groups that differ predictably in a wide range 
of other age-sensitive traits. Among the possible biomarkers, 
risk factors for mortality have a special status; many of them 
are already well defined for humans and are of special interest 
to physicians and insurers. Risk factors for death may or may 
not eventually prove useful as biomarkers of aging. Some risk 
factors, such as smoking history, propensity for seat belt use, 
and having recently been taken captive in a prison riot, are 
clearly associated with increased mortality risk but do not 
seem likely to serve well as indices of aging. Other factors, 
such as genes predisposing to Alzheimer’s disease or myocar- 
dial infarction, raise all-cause mortality risks by effects on 
specific common illnesses but, again, are probably not useful 
monitors of an underlying aging process with effects on a 
wide spectrum of lethal and nonlethal late-life changes. 
Showing that an assay not only predicts subsequent mortality 
but also correlates in plausible ways with other age-sensitive 
traits is a minimal standard to which proposed biomarkers 
must be held (see Figure 2 for an example of such an ap- 
proach). 
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Figure 2. Biomarker validation: a mouse example. The top panel 
shows results of a study of 42 male and female genetically 
heterogeneous mice (Faulkner, van der Meulen and Miller, un- 
published data). Each mouse was tested at 20 months of age to 
determine the fraction of the peripheral blood CD4 T cell subset 
that expressed the surface markers of memory T cells; this trait 
typically increases with age. Each mouse was tested at 22 months 
of age for muscle force generation; this trait typically declines 
with age. The negative correlation suggests that mice with high 
CD4 memory cells (“old” immune systems) also have poor force 
generation (“old” muscles). The bottom panel shows results 
from a separate study of 76 female mice from the same geneti- 
cally heterogeneous stock. Mice that had high levels of CD4 
memory cells at 18 months of age were found to have signifi- 
cantly lower remaining life expectancy than siblings with lower 
levels of CD4 memory T cells at the same age. Taken together, 
these results suggest that CD4 memory T cells might be able to 
serve as a biomarker of aging in mice. 
Comprehensive, well validated sets of innocuous tests of 
individual age would be of very great value for gerontological 
research, in the same way that the invention of the sphygmo- 
manometer served as a critical step in hypertension research. 
O n  a theoretical plane, such tests would provide a major 
pillar of support for the single process model of aging. They 
would provide a useful stimulus to mechanistic biogerontol- 
ogy, challenging molecular and cellular scientists to find the 
hidden links connecting diverse biomarkers to a central pace- 
maker. In the practical sphere, sets of biomarkers would 
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facilitate short-term tests of antigeric interventions. The de- 
velopment of a set of useful biomarkers of aging in monkeys, 
from a much larger set of age-sensitive variables tested for 
their reproducibility and their ability to track longitudinal 
changes in individual animals, has already started to demo?; 
strate the potential power of the biomarker approach 
through an analysis of blood antioxidant levels as modula- 
tors of aging rate and disease risks. Extension of this pioneer- 
ing work to more tractable or more self-conscious species 
(mice and humans, respectively) will deserve landmark sta- 
tus, if it can be done at  all. 
CALORIC RESTRICTION 
It has been known for more than 50 years that rodents, if 
fed a nutritionally complete diet that contains about 40% 
fewer calories than they would choose to consume given free 
access to food, live up to 50% longer than rats or mice on an 
ad libitum diet. This lifespan extension, a robust phenome- 
non that has now been repeated in dozens of laboratories 
using many different strains of mice and rats, does not merely 
represent a retardation of one or a small group of lethal 
diseases but seems to involve a genuine deceleration of the 
aging process as a whole in that a very wide range of bio- 
chemical, genetic, and physiological concomitants of aging 
seem to be retarded in parallel.5~2s Although the largest effects 
are seen when the restricted diet is begun early in life, restric- 
tion extends lifespan even when imposed in middle-age.26 
Both mean and maximal lifespan are affected. Many early 
ideas about the mechanism of the caloric restriction (CR) 
effect have been refuted, including the suggestions that CR 
worked by retardation of growth, by reducing the ingestion 
of toxic  substance^,^^ or by lowering the amount of energy 
utilization per gram of metabolizing tissue.” The idea that 
the CR protocol merely restores “normal” levels of food 
intake, i.e., those an animal would consume in the wild, 
seems inconsistent with the observation that restricted rats, 
unlike rats in nature, are largely infertile.29 
One obvious challenge is to discover how CR works to 
retard so many aspects of biological aging, including the 
age-adjusted incidence rates of almost all the common late- 
life diseases seen in rodents. Many plausible suggestions are 
based on well documented effects of CR, including dimin- 
ished blood glucose and insulin  level^,^" increases in free 
glucocorticoid  level^,^' altered expression of heat shock 
genes,32 and changes in resistance to free radical-mediated 
damage:13 The difficulty is to discover which of these alter- 
ations are primary, which are secondary but mechanistically 
critical, and which are merely incidental. Increased emphasis 
on the initial effects of CR may be helpful here, by discrimi- 
nating between changes that “merely” represent the deceler- 
ation of changes normally seen in aging animals and those 
that are seen relatively early after imposition of the CR diet 
and not typically affected by aging per se. The latter class of 
phenomena is likely to include some of the primary effects by 
which CR works its wonders but will also include CR- 
dependent effects that are independent of its interactions with 
aging. CR mice, for example, may have relatively low levels 
of muscle force generation, not because this is characteristic 
of young animals, but because CR mice are small, with 
correspondingly diminished muscle cross-sections. 
Showing that CR retards aging in primates will also 
qualify for landmark status. At least three studies are already 
underway that could help to settle this important ques- 
tion34-36. , each has shown some mildly encouraging prelimi- 
nary results, but none has settled the issue, nor can a speedy 
answer be expected from lifespan studies of such long-lived 
animals. An approach based on biomarkers would clearly be 
helpful in primate studies, and validation of biomarkers in 
monkeys is making excellent progres~,’~ but researchers will 
need to beware of the tempting, but fallaciously circular, 
assumption that interventions that alter candidate biomark- 
ers must necessarily be influencing the aging process. Studies 
of inter-individual variation in the efficiency of fuel utilization 
may also lend themselves to use in studies of primates, includ- 
ing humans: people who, like CR rodents, maintain low 
glucose and insulin levels while converting a high proportion 
of fuel to work might in principle constitute a subset whose 
metabolism already resembles those of restricted animals. 
A detailed mechanistic understanding of caloric restric- 
tion could have dramatic implications for disease prevention. 
The extension of healthy lifespan already achieved in labora- 
tory animals by the CR method is proportionally greater than 
that which would be achieved in humans by the combined 
elimination of all cardiovascular disease, cancer, and diabe- 
tes.17 Furthermore, CR rodents are not frail and debilitated 
for an extended period at the end of the lifespan. In fact, they 
are remarkably robust; given access to a running wheel, for 
example, they spontaneously run several kilometers/day at 
ages at which nearly all control animals have long since died 
(Figure 3).  A method to reproduce the CR effect pharmaco- 
logically would be worth a pretty penny and seems no less 
difficult to develop than, say, a cure for breast cancer or 
Alzheimer’s disease. Developing methods to reproduce some 
of the key secondary effects of the CR protocol, such as 
alterations in glucocorticoid levels or in glucose/insulin ra- 
tios, might also deserve attention, initially in animal models 
and eventually in clinical trials. 
Running Activity 
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Figure 3. Spontaneous exercise activity by rats on a restricted 
calorie diet. Control rats (squares) given free access to an exercise 
wheel run approximately 1 km/day initially, but this activity 
declines to less than 200 &day by the age of 12 months. In 
contrast, calorie-restricted rats (circles) average more than 4 
km/day until more than 30 months of age and are still running 
more than 1 krdday at ages at  which nearly all of the control 
animals have died. Figure courtesy of Dr. Roger McCarter.” 
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VERTEBRATE GENETICS. 
Genetic experiments that take months to perform in flies 
can take years or decades to carry out in mice, and would, if 
ethically permissible, take centuries to attempt in humans. 
The attraction of mouse genetics for experimental gerontol- 
ogy thus arises not from its convenience or simplicity but 
from the plausible guess that mouse aging and human aging 
are as closely related as the anatomy and cell biology of these 
two species: i.e., not awfully close, but maybe close enough to 
do  the trick. The key unanswered question here is whether the 
number of genes controlling aging rate are few enough that 
each one may have an effect large enough to be detected in 
studies cheap enough to be practical. This question, simple to 
pose, proves to be hard to answer with confidence on current 
evidence. It is clear that there are thousands of genes at which 
mutations can affect lifespan, usually by leading to a life- 
shortening disease. The trickier question is whether some loci 
also affect lifespan by a general effect on the aging process. 
Such a locus would be identifiable if it affected not merely the 
likelihood of a single lethal illness, or a small number of 
related illnesses (e.g., a variety of lymphomas) but instead 
altered the incidence of most or all late-life illnesses and, at  
the same time, altered the pace of a wide range of age- 
sensitive changes. The questions to be answered, in rough 
order, are three: how many such loci are there, where are they 
located, and what do they do? There are  hint^^',^^ that major 
differences in longevity can be brought about by differences in 
as few as 3 to 12 genes (or, more precisely, groups of closely 
linked genes), but these studies are still fragmentary and not 
fully convincing. The recent availability of easily scored ge- 
netic markers that discriminate among various mouse strains 
has made possible an approach, called quantitative trait locus 
(QTL) mapping, that may, in the next few years, provide the 
first compelling data on the location of mouse genes that 
influence longevity. 
Success of the QTL approach would have important 
long-term and short-term consequences for biomedical ger- 
ontology. In the short term, it would be important to see the 
extent to which the implicated chromosomal regions also had 
effects on multiple aspects of the aging process. If, for exam- 
ple, one or more of the genetic markers found by QTL 
mapping were also found to influence the rate of decline of 
immune function, muscle strength, and wound healing in 
aging mice, this would lend powerful support to the “single 
process” models of aging, and spur interest reciprocally in the 
QTL loci themselves. Mice differing at one or several QTL 
could also be used to test specific mechanistic ideas about the 
control of aging: if a group of mice selected for a specific set of 
QTL were found to live long and healthy lives, but not to 
differ from their sibs in, say, antioxidant defenses, this would 
provide potent evidence against the free radical theories of 
aging. Strong evidence that one or more markers was linked 
to loci that influenced a wide range of age-dependent changes 
would provide a rationale for the very difficult work needed 
to identify and clone the effective genes themselves. Studies of 
the effects of segregating portions of the homologous human 
chromosomal regions could be initiated well before the clon- 
ing of the mouse genes themselves and might help to test the 
usefulness of the mouse genetic systems as decent models for 
the human genetics of aging. Success in any of these projects 
would merit landmark status and help to put experimental 
gerontology on a rational footing. 
The QTL approach, though, is likely to fail for one of 
two reasons. It may be that there are too many loci at which 
variations contribute to individual differences in aging rate; if 
so, the contribution of any one such locus would be too small 
to detect. An alternate, and less intractable, reason for failure 
might reflect a peculiarity of the world’s pool of laboratory 
mice: their minuscule stock of genetic variation, particularly 
at loci that might in principle have an effect on aging. Like 
cheetahs?’ nearly all laboratory mice are derived from a very 
small number of ancestral animals. This “founder” effect 
might by itself have accidentally rid the laboratory mouse 
gene pool of variation at  the hypothetical age-controlling 
alleles. Worse still, the very strong and unintended selection 
that accompanies adaptation to laboratory life - selection for 
tameness, for rapid sexual maturation and large litters, and 
for loss of loci that coordinate life history to seasonal varia- 
t i o n ~ ~ ~  and periods of food scarcity - create a gene pool that 
is radically altered and altered in ways that may select against 
high longevity alleles. In the evolutionary context- high 
predation pressure leading to rapid development and rapid 
aging-the laboratory scientist serves most laboratory mice 
as predator extruordinuire, ruthlessly selecting against geno- 
types that delay reproduction. This potential obstacle, how- 
ever, can potentially be overcome, by starting the genetic 
analysis with mice freshly trapped from wild populations, 
preferably from island stocks in which natural selection may 
already have selected for genotypes with delayed maturation 
and delayed senescence. 
CELLULAR SENESCENCE 
If the educated layperson (a first year medical student, 
for example) knows anything about the experimental biology 
of aging, he/she knows that normal cells can’t continue to 
divide forever. The report42 that human diploid fibroblast 
cultures are limited in the number of cell divisions they can 
accomplish before ceasing to replicate has entranced a gener- 
ation of cellular gerontologists. The intuition that this cell 
culture system is in some sense a model for aging of intact 
organisms is viewed as whimsical by skeptics, but even the 
skeptical acknowledge that study of the “Hayflick limit” 
continues to motivate high quality research on a variety of 
major problems in cell growth control and differentia- 
tion.43-46 Ten years ago the principal challenge for the stu- 
dents of in vitro senescence was to work out the molecular 
basis for growth cessation in late passage cells; this important 
problem, though not yet fully solved, has clearly begun to 
yield, and it is now reasonably easy to see the outline of the 
eventual solution. The new challenge, still only tentatively 
faced, will be to determine whether the phenomenon of in 
vitro senescence bears an important relationship to, or sheds 
new light on, the aging process that turns teen-agers into 
geriatric cases. 
One important goal will be to determine if cellular senes- 
cence occurs in vivo and, if so, at what ages and in which 
tissues of what organisms. One obstacle has been the lack of 
unambiguous single-cell assays that can distinguish late- 
passage cells from their early-passage progenitors and, thus, 
serve plausibly as an marker for senescent cells in intact 
organisms. One promising report4’ has shown that skin of 
older (but not younger) persons includes a small proportion 
of fibroblasts and keratinocytes that express a P-galactosi- 
dase isoform characteristically seen in late-passage fibroblast 
cultures, Extension of this approach to the analysis of other 
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cell types in other tissues, and development of other similar 
markers, including some suitable for use in rodent studies, 
will be very helpful in testing hypotheses about the presence 
of cells, in older individuals, whose properties resemble those 
seen in late passage cell cultures. New ideas and new ap- 
proaches are also needed to address the related issue of 
whether senescent cells, if they are present at  all in tissues of 
aged subjects, contribute at  all to disease pathogenesis and 
organ dysfunction. In this context it may be helpful to redi- 
rect attention away from the final stages in the course of in 
vitro senescence, i.e., those related to growth cessation, to 
changes that occur in middle-passage cultures, inasmuch as 
cells at  these intermediate stages may prove to be more 
common in the tissues of aging individuals. Other properties 
of senescent fibroblasts, such as secretion of collagenase4* or 
resistance to a p o p t ~ s i s , ~ ~  may prove to be particularly impor- 
tant as mediators of pathophysiological changes in old age. 
The idea that the length of telomeres (the terminal seg- 
ments of chromosomes) may provide a way of counting 
numbers of cell divisions has led to studies showing a trend 
towards shorter telomeres both in late passage cultures and in 
some cell types of aging people,46.s0,”’ and there are some 
data, preliminary but provocative, to suggest that short telo- 
mere lengths may be characteristic of endothelial cells in 
atherosclerosis-prone regions of the vascular tree.s2 Early, 
influential, models for age-dependent changes in telomere 
length depicted the trajectory of telomere length, like the 
aging process, as essentially a one-way street, in which the 
silencing of the enzyme telomerase in early embryogenesis 
prevented further increases in telomere lengths, which then 
shortened progressively at each cell division because of well 
documented properties of the polymerase that synthesizes 
DNA.’3 Over-short telomeres were postulated to promote 
neoplastic transformation via chromosomal rearrangements 
and to lead to cell growth cessation by processes still to be 
elucidated. Activation of telomerase was seen as a key step in 
the development of malignant tumors, enabling them to 
overcome the barrier to indefinite growth that would other- 
wise be imposed by the Hayflick limit.s4 This appealing 
picture has been complicated recently by demonstrations that 
telomerase activity can be detected in at  least some normal 
cellsSS and that telomere length in neoplastic cells can be 
modulated by telomere-binding factorssh that block telomer- 
ase function, while the role of telomere shortening in growth 
cessation a t  late passages has also been q~estioned.~’ A 
thorough understanding of the role of cellular senescence as a 
barrier to malignancy, and the possible role of telomere 
length in both processes, might help to clarify the nature of 
the linkage between cancer, aging, and species-specific max- 
imum lifespan. 
The ability of aging to alter the properties of cells that are 
unable to divide in adult life has always posed a stumbling 
block for devotees of systems for studying growth cessation 
in late passage cells and for their latter-day cousins the 
telomere specialists. While it is possible to devise possible 
connections between a loss of cell proliferative function and 
secondary changes in nonproliferative cells and extracellular 
tissues, attempts to test these possible links are still at a very 
early stage. The difficulty of concocting a theory that explains 
the parallel loss of adaptive function in so many cell and 
tissue types is, of course, a major obstacle for most theories of 
aging, not only for those that focus on changes in cellular 
proliferation. 
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LINKS TO DISEASE 
One way to put the strength of the links between aging 
and disease into perspective is to note that the risk, each day, 
of a single cell undergoing the transformation that develops 
into a fatal neoplasia is about 100,000-fold lower in humans 
than in mice. The cancer risk in humans, i.e., the risk of first 
noticing a cancer that if left untreated would be fatal, is about 
.42% per year, while the corresponding risk in mice is about 
20% per year, a 50-fold difference. This contrast, already 
dramatic, is magnified still further by the difference in the size 
of the target population. Most cancers are clonal in origin, 
and a 10-fold increase in cell number ought, all things being 
equal, to lead to a 10-fold increase in the likelihood that any 
one cell will accomplish each of the steps that convert normal 
to malignant cells. The 2000-fold increase in cell size that 
produced 70-kg humans from some 35-gm mouse-like ances- 
tor should thus have led to a 2000-fold increase in cancer risk 
per animal per day, not the 50-fold decrease that is, in fact, 
observed. Evolution, in producing long-lived big animals, 
needs somehow to build in a defense system that reduces per 
cell malignancy rates by five orders of magnitude. Merely 
reducing the rate of one kind of cancer, say mammary ade- 
nocarcinoma, by 100,000 fold would not be enough because 
the resulting large animal, with incidence risks of all other 
cancers left at the “mouse-normal” rate, would be virtually 
certain to die before age 5 to 10 of some other tumor type, 
perhaps lymphoma or hepatoma. And merely reducing by 
100,000 fold the rates for all forms of neoplastic disease 
would also be useless unless evolution managed simulta- 
neously to prevent the decline in immunity, muscle strength, 
wound healing, and neural responsiveness that would greatly 
impair survival in mice that managed to avoid cancers by 5 or 
10 years of age. A cure for aging, something that evolution 
has managed to accomplish many times in the development 
of long-lived, large animals in multiple mammalian lineages, 
and which gerontologists have been able to mimic (partially) 
for decades by caloric restriction in rodents, is effectively a 
cure for disease. 
Developing a cure for aging might take a while; in the 
meantime, experimental pathologists can turn their attention 
to the related problem of discovering the mechanisms that 
link specific diseases of interest to the aging process. The 
challenge proposed here is not the familiar (and noble) one of 
working out the cause of specific diseases, the causes of 
cancer and atherosclerosis and sarcopenia and immunosenes- 
cence, but instead to learn more about why these and other 
maladies are postponed so dramatically in humans, bats, and 
some birds and correspondingly accelerated in mice, opos- 
sums, and other short-lived mammals. Studies of closely 
related species, races, and subspecies, Chihuahuas versus 
wolfhounds,” mainland versus island opossums,’ humans 
versus rhesus versus lemurs,” and species that have similar 
sizes but radically different lifespans,’2 may be particularly 
germane. Well specified mechanistic theories (e.g., “the 10- 
fold lower cancer risk in the 8-year-old Chihuahua, compared 
with similarly aged wolfhounds, results from improved effi- 
ciency of repair of DNA damage throughout the adult lifes- 
pan”) can be tested and either discarded or, if supported by 
the evidence, tested again in other comparative contexts. 
Comparisons within species may also be informative; it 
would be interesting to know if the genetic factors that lead to 
similar longevity in identical twins12 or, to a lesser extent, 
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among first degree relatives, also influence such factors as 
immune function, muscle function, insulin sensitivity, DNA 
repair, or other traits of interest. Synthetic genetics may also 
provide useful leverage; it would be interesting to know, for 
example, if mice engineered for improved protection against 
free radicals, or selected for high levels of immune respon- 
s i v e n e ~ s , ~ ~  show parallel retardation in a number of age- 
dependent processes, including risks of a variety of diseases. 
SUMMARY 
When will the biology of aging become useful? Doing 
basic science requires a leap of faith. The trapeze artist, 
flinging herself backwards off her perch, makes the reason- 
able assumption that her partner will once again swoop into 
the spotlight in the nick of time to prevent the embarrassment 
of a missed connection, and she is seldom disappointed. The 
basic scientist, similarly vulnerable, arguing the case for basic 
research against the claims of others who maintain that the 
money could be more profitably spent on problems whose 
solutions are easier to envision, must try to avoid looking 
down to the circus ring below, filled as it is with the mangled 
remains of basic research ideas whose uselessness has already 
been amply proven. Is there any way to improve the chances 
that the direction in which we hurl our careers (and the 
hard-earned dollars of our sponsors) will indeed contain 
something to grab at the other end of the arc? Our colleagues, 
hard at  work learning how to improve the well-being of the 
seriously ill, or adding a methyl group here and there to drugs 
that already work somewhat, or delineating the detailed 
pathogenesis of common diseases whose mechanisms are 
already fairly well understood, can feel justifiably proud of 
their own accomplishments and confident that the future will 
hold more along the same lines. They have earned the right to 
wonder when, if ever, studies of the biology of aging will 
come of age. Those of us who urge increased support for 
studies of the fundamental biology of aging can recite lists of 
basic science that did indeed make the big time - studies of 
DNA-cutting enzymes, of subatomic particles, of mutant 
fruit flies, of game theory - but in our hearts we know that 
this bravado cannot substitute for proof that we know some- 
thing important about how aging works and can do some- 
thing with that knowledge. 
The most valuable landmarks are those described by a 
guide who has been there and seen the territory. In the current 
situation, alas, no such guide is available, and the territory 
itself may prove to be terra ficta rather than terra firma. A 
speculative essay of this kind, however cautiously phrased, is 
bound to contain ideas that will seem childishly naive 10,20 
or 50 years hence. One can hope, however, that further 
attention to the basic biology of the aging process, and the 
links that connect aging to late-life disease, will hasten the 
day when we can identify and discard the dead-end ideas and 
begin to earn our keep in a newly fledged science of applied 
biogerontology . 
ACKNOWLEDGMENTS 
The author thanks Steven Austad for his unpublished 
calculations on species lifespans in relation to fibroblast 
growth limits and for valuable tutorials on comparative 
biology; Kevin Flurkey and David Harrison for unpublished 
results on the longevity of dw/dw mice; Roger McCarter for 
data on the athletic prowess of famished rats; and David 
Burke and Vince Cristofalo for comments on the manuscript. 
REFERENCES 
1. Masoro EJ. Aging: current concepts. In: Masoro EJ, ed. Handbook of Physi- 
ology. Section 11: Aging. New York: Oxford University Press, 1995. 
2. Austad SN, Fischer KE. Mammalian aging, metabolism, and ecology: Evi- 
dence from the bats and marsupials. J Gerontol Biol Sci 1991;46:847-53. 
3. Austad SN. Retarded senescence in an insular population of Virginia opos- 
sums. J Zoo1 Lond 1993;229:695-708. 
4. Finlay BL, Darlington RB. Linked regularities in the development and evolu- 
tion of mammalian brains. Science 1995;268:1578-1584. 
5. Weindruch R, Walford RL. The retardation of aging and disease by dietary 
restriction. Springfield, IL Charles C Thomas, 1988. 
6. Williams GC. Pleiotropy, natural selection, and the evolution of senescence. 
Evolution 1957;11:398-411. 
7. Hutchinson EW, Rose MR. Quantitative genetics of postponed aging in Dro- 
sophila melanogaster. 1. Analysis of outbred populations. Genetics 
199 1; 127:719-727. 
8. Luckinbill LS, Arking R, Clare MJ et al. Selection for delayed senescence in 
9. Promislow DE. On size and survival: Progress and pitfalls in the allometry of 
Drosophilia melanogaster. Evolution 1984;38:996-1003. 
life span. J Gerontol 1993;48:8115-123. 
10. Austad SN. Comparative aging and life histories in mammals. Exp Geronrol 
11. Austad SN, Fischer KE. Primate longevity: Its place in the mammalian 
12. K u  HH, Sohal RS. Comparison of mitochondria1 pro-oxidant generation 
1997;32:23-38. 
scheme. Am J Primatol 1992;28:251-261. 
and anti-oxidant defenses between rat and pigeon: Possible basis of variation 
in longevity and metabolic potential. Mech Ageing Dev 1993;72:67-76. 
13. Reznick DN, Shaw FH, Rodd FH et al. Evaluation of the rate of evolution in 
natural populations of guppies (Poecilia reticulata). Science 1997;275:1934- 
1937. 
long as wild type. Nature 1993;366:461-464. 
longevity in Caenorhabditis elegans. Genetics 1995;139: 1567-1583. 
dismutase and catalase in Drosophila melanogaster. Science 
14. Kenyon C, Chang J, Gensch E et al. A C.elegans mutant that lives twice as 
15. Larsen PL, Albert PS, Riddle DL. Genes that regulate both development and 
16. Orr WC, Sohal RS. Extension of life-span by overexpression of superoxide 
1994;263:1128-1130. 
17. Yu CE, Oshima J, Fu YH et al. Positional cloning of the Warner’s syndrome 
18. Harrison DE. Potential misinterpretations using models of accelerated aging. 
19. Partridge L, Harvey PH. Methusalah among nematodes. Nature 
20. Brown-Borg HM, Borg KE, Meliska CJ et al. Dwarf mice and the ageing 
21. Li Y, Deeb B, Pendergrass W e t  al. Cellular proliferative capacity and life 
gene. Science 1996;272:258-262. 
J Gerontol Biol Sci 1994;49:B245. 
1993;366:404-405. 
process. Nature 1996;384:33. 
span in small and large dogs. J Gerontol A Biol Sci. Med. Sci. 
1996;5 1 :B403-408. 
22. Johnson TE, Lithgow GJ, Murakami S. Hypothesis: Interventions that in- 
crease the response to stress offer the potential for effective life prolongation 
and increased health. J Gerontol A Biol Sci Med Sci 1996;51:B392-395. 
23. Costa PT, McCrae RR. Design and analysis of aging studies. In: Masoro EJ, 
ed. Handbook of Physiology. Section 11: Aging. New York: Oxford Univer- 
sity Press, 1995. 
nants of the rate of biological aging in pigtailed macaques (Macaca nemest- 
rina). J Gerontol Biol Sci 1997;52A:B26-38. 
25. Yu BP. Putative Interventions. In: Masoro EJ, ed. Handbook of Physiology. 
Section 11: Aging. New York: Oxford University Press, 1995, pp 613-631. 
26. Weindruch R, Walford RL. Dietary restriction in mice beginning at 1 year of 
age: Effect on life span and spontaneous cancer incidence. Science 
24. Short R, Williams DD, Bowden DM. Circulating antioxidants as determi- 
1 982;215: 1 415-141 8. 
27. Masoro EJ. Food restriction in rodents: An evaluation of its role in the study 
of aging. J Gerontol 1988;43:B59-64. 
28. McCarter R, Masoro EJ, Yu BP. Does food restriction retard aging by reduc- 
ing the metabolic rate? Am J Physiol 1985;248:E488-490. 
29. Merry BJ, Holehan AM. Onset of puberty and duration of fertility in rats 
fed a restricted diet. J Reprod Fertil 1979;57:253-259. 
30. Masoro EJ, McCarter RJ, Katz MS et al. Dietary restriction alters character- 
istics of glucose fuel use. J Gerontol 1992;47:8202-208. (Published erratum 
appears in J Gerontol 1993 Mar;48(2):B73). 
31. Sabatino F, Masoro EJ, McMahan CA et al. Assessment of the role of the 
glucocorticoid system in aging processes and in the action of food restric- 
tion. J Gerontol Biol Sci 1991;46:B171-179. 
32. Heydari AR, Conrad CC, Richardson A. Expression of heat shock genes in 
JAGS OCTOBER 1997-VOL. 45, NO. 10 THE BIOLOGY OF AGING 1267 
hepatocytes is affected by age and food restriction in rats. J Nutr 
1995;125:410-418. 
of cellular homeostasis. Proc Soc Exp Biol Med 1990;193:13-15. 
male rhesus monkeys: design, methodology, and preliminary findings from 
the first year of study. J Gerontol 1993;4X:B17-26. 
3 ~ .  Lane MA, Ball SS, lngram DK et al. Diet restriction in rhesus monkeys low- 
ers fasting and glucose-stimulated glucoregulatory end points. Am J Physiol 
1995;26X:E941-94X. 
older-aged rhesus monkeys: Effects on insulin resistance. J Gerontol A Biol 
Sci Med Sci 1995;50:B142-147. 
upper limits to human longevity. Science 1990;250:634-640. 
ness, life span, and disease incidence in interline crosses of mice selected for 
high or low multispecific antibody production. J lmmunol 1989;142:1224- 
1234. 
39. Gelman R, Watson A, Bronson R et al. Murine chromosomal regions corre- 
lated with longevity. Genetics 1988;118:693-704. 
40. O’Brien SJ, Roelke ME, Marker Let  al. Genetic basis for species vulnerabil- 
ity in the cheetah. Science 1985;227:1428-1434. 
41. Ebihara S, Marks T, Hudson DJ et al. Genetic control of melatonin synthesis 
in the pineal gland of the mouse. Science 1986;231:491-493. 
42. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell 
strains. Exp Cell Res. 1961;25:585-621. 
43. Campisi J, Dimri G, Hara E. Control of replicative senescence. In: Schneider 
EL, Rowe JW, eds. Handbook of the Biology of Aging. New York: Aca- 
demic Press, 1996, pp 121-149. 
44. Goldstein S. Replicative senescence: The human fibroblast comes of age. Sci- 
ence 1990;249: 1 129 -1 133. 
45. Pereira-Smith OM, Smith JR. Genetic analysis of indefinite division in hu- 
man cells: Identification of four complementation groups. Proc Natl Acad 
Sci USA 1988;85:6042-6046, 
33. Yu BP, Lee DW, Marler CG et al. Mechanism of food restriction: Protection 
34. Kemnitz JW, Weindruch R, Roecker EB et al. Dietary restriction of adult 
36. Bodkin NL, Ortmeyer HK, Hansen BC. Long-term dietary restriction in 
37. Olshansky SJ, Carnes BA, Cassel C. In search of Methuselah: Estimating the 
38. Covelli V, Mouton D, Di Majo Ve t  al. Inheritance of immune responsive- 
46. Vaziri H, Schachter F, Uchida 1 et al. Loss of telomeric DNA during aging of 
normal and trisomy 21 human lymphocytes. Am J Hum Genet 
1993;52:661-667. 
cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 
1995;92:9363-9367. 
48. Campisi J. Aging and cancer: The double-edged sword of replicative senes- 
cence. J Am Geriatr Soc 1997;45:482-488. 
49. Wang E. Senescent human fibroblasts resist programmed cell death, and fail- 
ure to suppress bc12 is involved. Cancer Res 1995;.55:2284-2292. 
50. Harley CB, Futchcr AB, Greider CW. Telomeres shorten during ageing of 
human fibroblasts. Nature 1990;345:458-460. 
51. Wcng NP, Levine BL, June CH et al. Human naive and memory T lympho- 
cytes differ in telomeric length and replicative potential. I’roc Natl Acad Sci 
USA 1995;92:11091-11094. 
52. Chang E, Harley CB. Telomere length and replicative aging in human vascu- 
lar tissues. Proc Natl Acad Sci USA 1995;92:11190-11194. 
53. Chiu CP, Harley CB. Replicative senescence and cell immortality: The role 
of telomeres and telomerase. Proc Soc Exp Biol Med 1997;214:99-106. 
54. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human 
telomerase activity with immortal cells and cancer. Science 1994;266:2011- 
2015. 
lymphocytes and hematopoietic progenitor cells. J lmmunol 1995;155:3711- 
3715. 
56. van Steensel B, de Lange T. Control of telomere length by the human telo- 
meric protein TRFI. Nature 1997;385:740-743, 
57. Smith JR, Pereira-Smith OM. Replicative senescence: implications for in vivo 
aging and tumor suppression. Science 1996;273:63-67. 
5X. Rohme D. Evidence for a relationship between longevity of mammalian spe- 
cies and life-spans of normal fibroblasts in vitro and erythrocytes in vivo. 
Proc Natl Acad Sci USA 1981;78:5009-5013. 
59. McCarter RJM, Shimokawa I, Ikeno Yet al. Physical activity as a factor in 
the action of dietary restriction on aging: Effects in Fischer 344 rats. Aging 
Clin Exp Res 1997;9:73-79. 
47. Dimri GP, Lee X, Basile G et al. A biomarker that identifies senescent human 
55. Hiyatna K, Hirai Y, Kyoizumi S et al. Activation of telomerase in human 
